公开(公告)号：US20160051532A1

公开(公告)日：2016-02-25

申请号：US14933801

申请日：2015-11-05

Applicant: Exelixis, Inc.

Inventor： Dana T. Aftab ,  Frauke Schimmoller

IPC: A61K31/47

CPC classification number: A61K31/47

Abstract: This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.

公开(公告)号：US20150196545A1

公开(公告)日：2015-07-16

申请号：US14668312

申请日：2015-03-25

Applicant: Exelixis, Inc.

Inventor： Dana T. Aftab ,  Frauke Schimmoller

IPC: A61K31/47

CPC classification number: A61K31/47

Abstract: This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.

Abstract translation: 本发明涉及用MET和VEGF的双重抑制剂如化合物1治疗癌症，特别是眼部黑色素瘤。

公开(公告)号：US11116759B2

公开(公告)日：2021-09-14

申请号：US16142691

申请日：2018-09-26

Applicant: Exelixis, Inc.

Inventor： Dana T. Aftab ,  Frauke Schimmoller

IPC: A61K31/47 ,  A61P35/04

Abstract: This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.

公开(公告)号：US20190091215A1

公开(公告)日：2019-03-28

申请号：US16142691

申请日：2018-09-26

Applicant: Exelixis, Inc.

Inventor： Dana T. Aftab ,  Frauke Schimmoller

IPC: A61K31/47

Abstract: This invention is directed to the treatment of cancer, particularly ocular melanoma, with a dual inhibitor of MET and VEGF such as Compound 1.

公开(公告)号：US20140323522A1

公开(公告)日：2014-10-30

申请号：US14356927

申请日：2012-11-08

Applicant: Exelixis, Inc.

Inventor： Dana T. Aftab ,  Frauke Schimmoller

IPC: A61K31/47

CPC classification number: A61K31/47 ,  A61K31/517

Abstract: This invention is directed to the treatment of cancer, particularly castration-resistant prostate cancer and bone metastases, with a dual inhibitor of MET and VEGF.

Abstract translation: 本发明涉及用MET和VEGF的双重抑制剂治疗癌症，特别是去势抗性前列腺癌和骨转移。